Trial0

Clinical trial · NCT07425106

Comparative Study of High Performance Low-Cost Optical Coherence Tomography (Stage 1B, 2 and 3)

Enrolling by invitation

Sponsor: Duke University

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

The purpose of this study is to complete performance testing of our custom optical coherence tomography (OCT) device to verify it can deliver retinal images of similar quality to a commercial OCT device. We will then add an angle-resolved low coherence interferometry (a/LCI module) to the device to make measurements of retinal tissue structure.

Interventions

  • retinal imaging with low-cost OCT-a/LCI device · DEVICE

    retinal imaging with low-cost OCT-a/LCI device

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

All Participants:

Inclusion Criteria:

* able to provide informed consent

Exclusion Criteria:

* potentially confounding ocular conditions, such as: glaucoma, current corneal injury, retinal damage, diabetes, corrected distance visual acuity worse than 20/40
* eyes that have had intraocular surgery or retinal surgery, other than cataract surgery

Participants with Alzheimer's Disease:

Inclusion:

\- mild cognitive impairment (MCI) or dementia due to Alzheimer's disease, confirmed by A/T/N classification

Healthy Controls:

Exclusion:

\- has a memory or other neurodegenerative diagnosis (including mild cognitive impairment, Parkinson's disease, Alzheimer's disease, traumatic brain injury, post-traumatic stress disorder)

If two eyes satisfy the inclusion / exclusion criteria, both eyes will be included in the study. If only one eye satisfies the criteria, only the qualifying eye will be included in the study.

Sites (1)

  • Duke University Medical Center, Durham, North Carolina

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-02-25.